Page last updated: 2024-08-24

topotecan and Cancer of Skin

topotecan has been researched along with Cancer of Skin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrade, LM; Brito, LB; Esteves, NLS; Gratieri, T; Lima, EM; Marreto, RN; Oliveira, GAR; Taveira, SF; Valadares, MC; Venâncio, JH	1
Ju, RJ; Li, N; Li, RJ; Lu, WL; Wang, XX; Wang, ZH; Yao, HJ; Yu, Y; Zhang, L; Zhang, Y; Zhou, J	1
Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ	1

Trials

1 trial(s) available for topotecan and Cancer of Skin

Article	Year
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome	2001

Article

Year

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.

Blood, 2001, Apr-01, Volume: 97, Issue:7

Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome

2001

Other Studies

2 other study(ies) available for topotecan and Cancer of Skin

Article	Year
Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers. The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:10 Topics: Administration, Topical; Animals; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Hydrogels; Lipids; Melanoma, Experimental; Mice; Nanoparticles; Organ Culture Techniques; Skin Absorption; Skin Neoplasms; Swine; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2017
Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials, 2012, Volume: 33, Issue:6 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liposomes; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Skin Neoplasms; Topotecan	2012

Article

Year

Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers.

The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:10

Topics: Administration, Topical; Animals; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Hydrogels; Lipids; Melanoma, Experimental; Mice; Nanoparticles; Organ Culture Techniques; Skin Absorption; Skin Neoplasms; Swine; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2017

Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.

Biomaterials, 2012, Volume: 33, Issue:6

Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liposomes; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Skin Neoplasms; Topotecan

2012